论文部分内容阅读
目的 :观察促肝细胞生长素联合苦黄注射液治疗慢性重型乙型病毒性肝炎 (乙肝 )的疗效。方法 :选择90例慢性重型乙肝患者 ,随机分为治疗组 5 7例 ,对照组 3 3例。对照组给予肝脑清、清蛋白、新鲜血浆、茵栀黄、门冬氨酸钾镁、胸腺肽等治疗 ,有腹水、出血倾向、肝性脑病、感染、电解质及酸碱平衡紊乱者均作相应对症处理。治疗组在上述用药的基础上不用茵栀黄 ,加用促肝细胞生长素 12 0 μg·d 1 ,苦黄注射液 3 0mg·d 1 ,分别加入 10 %葡萄糖注射液 2 5 0mL中静脉滴注。两组疗程 2 1～ 42d ,平均 3 2d。结果 :治疗组显效 2 0例 ,有效 2 3例 ,无效 14例 ,有效率 75 .4%。对照组显效 4例 ,有效 11例 ,无效 18例 ,有效率 45 .5 %。两组有效率比较差异有显著性 (P <0 .0 5 )。实验室指标总胆红素 (T BiL)、ALT、AST、清蛋白、凝血因子Ⅱ活动度 (PTA)明显好转 ,与治疗前及对照组相比差异均有显著性 (P <0 .0 5 )。结论 :促肝细胞生长素联合苦黄治疗慢性重型乙肝可减轻患者临床症状、改善实验室指标、提高生存率 ,无明显不良反应 ,值得推广应用
Objective: To observe the effect of hepatocyte growth-promoting hormone combined with Kuhuang injection in the treatment of chronic severe hepatitis B (hepatitis B). Methods: Ninety patients with chronic severe hepatitis B were selected and randomly divided into treatment group (57 cases) and control group (33 cases). The control group was treated with Hepato-Qingrao, albumin, fresh plasma, Yinzhihuang, potassium-magnesium aspartate and thymosin, with ascites, bleeding tendency, hepatic encephalopathy, infection, electrolytes and acid- Symptomatic treatment. The treatment group on the basis of the above medication without Yinzhihuang, plus the use of promoting hepatocyte growth factor 120μg · d 1, Kuhuang injection 30mg · d 1, were added 10% glucose injection of 250mL intravenous infusion Note. Two groups of treatment 2 1 ~ 42d, an average of 32d. Results: The treatment group was effective in 20 cases, effective in 23 cases, ineffective in 14 cases, effective rate was 75.4%. In the control group, 4 cases were markedly effective, 11 cases were effective, 18 cases were ineffective, and the effective rate was 45.5%. The difference between the two groups was significant (P <0.05). Laboratory indexes of total bilirubin (T BiL), ALT, AST, albumin, coagulation factor Ⅱ activity (PTA) were significantly improved compared with before treatment and control group, the difference was significant (P <0.05 ). Conclusion: HGF and Kuhuang treatment of chronic severe hepatitis B can reduce the clinical symptoms, improve the laboratory indicators, improve survival rate, no obvious adverse reactions, it is worth to promote the application